Stefano Maria Magrini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4371670/publications.pdf

Version: 2024-02-01

185 papers 3,790 citations

147786 31 h-index 168376 53 g-index

189

189 docs citations

189 times ranked 5088 citing authors

#	Article	IF	CITATIONS
1	Almost one year of COVID-19 pandemic: how radiotherapy centers have counteracted its impact on cancer treatment in Lombardy, Italy. CODRAL/AIRO-L study. Tumori, 2022, 108, 177-181.	1.1	2
2	Baseline prognostic factors affecting survival in recurrent and/or metastatic salivary gland adenoid cystic carcinoma. Oral Oncology, 2022, 126, 105764.	1.5	8
3	Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study. Minerva Urology and Nephrology, 2022, 74, .	2.5	5
4	The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study. Minerva Urology and Nephrology, 2022, 74, .	2.5	1
5	PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study. Clinical and Experimental Metastasis, 2022, 39, 443.	3.3	4
6	Stereotactic Radiotherapy and Androgen Deprivation Therapy for Localized Prostate Cancer: A Retrospective Mono-institutional Experience. In Vivo, 2022, 36, 306-313.	1.3	1
7	RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment. Cancers, 2022, 14, 2273.	3.7	1
8	Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study. Biomedicines, 2022, 10, 1321.	3.2	5
9	Clinical and pathological prognostic factors in Merkel cell carcinoma Journal of Clinical Oncology, 2022, 40, e21574-e21574.	1.6	О
10	Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness. Clinical Genitourinary Cancer, 2021, 19, 230-236.	1.9	53
11	Short fractionation radiotherapy for early prostate cancer in the time of COVID-19: long-term excellent outcomes from a multicenter Italian trial suggest a larger adoption in clinical practice. Radiologia Medica, 2021, 126, 142-146.	7.7	27
12	Non-metastatic ductal adenocarcinoma of the prostate: pattern of care from an uro-oncology multidisciplinary group. World Journal of Urology, 2021, 39, 1161-1170.	2.2	4
13	How radical prostatectomy procedures have changed over the last 10Âyears in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. World Journal of Urology, 2021, 39, 1445-1452.	2.2	0
14	COVID-19 safe and fully operational radiotherapy: An AIRO survey depicting the Italian landscape at the dawn of phase 2. Radiotherapy and Oncology, 2021, 155, 120-122.	0.6	5
15	Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1773-1779.	2.5	5
16	18F-FDG-PET/CT in laryngeal cancer: comparison with conventional imaging and prognostic role. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 229-238.	0.2	1
17	PROACTA: a survey on the actual attitude of the Italian radiation oncologists in the management and prescription of hormonal therapy in prostate cancer patients. Radiologia Medica, 2021, 126, 460-465.	7.7	8
18	Post-operative management of brain metastases: GRADE-based clinical practice recommendations on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Journal of Cancer Research and Clinical Oncology, 2021, 147, 793-802.	2.5	0

#	Article	IF	CITATIONS
19	The Italian Association of Radiotherapy and Oncology Recommendation for Breast Tumor Recurrence: Grades of Recommendation, Assessment, Development and Evaluation Criteria. Journal of Breast Cancer, 2021, 24, 241.	1.9	6
20	In reply to Fiorino et al.: The central role of the radiation oncologist in the multidisciplinary & multiprofessional model of modern radiation therapy. Radiotherapy and Oncology, 2021, 155, e20-e21.	0.6	3
21	CyberKnife for Recurrent Malignant Gliomas: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 652646.	2.8	7
22	Adjuvant radiotherapy and radioiodine treatment for locally advanced differentiated thyroid cancer: systematic review and meta-analysis. Tumori, 2021, 107, 489-497.	1.1	3
23	Impact of Gastrointestinal Side Effects on Patients' Reported Quality of Life Trajectories after Radiotherapy for Prostate Cancer: Data from the Prospective, Observational Pros-IT CNR Study. Cancers, 2021, 13, 1479.	3.7	5
24	Treatment of muscle-invasive bladder cancer in patients without comorbidities and fit for surgery: Trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation,) Tj ETQq0 0 0 r	gBT_/Overl	ock 10 Tf 50 5
25	and Clinical Oncology (AIRO). Critical Reviews in Oncology/Hematology, 2021, 159, 103235. Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study. Prostate Cancer and Prostatic Diseases, 2021, 24, 852-859.	3.9	11
26	MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancers, 2021, 13, 1791.	3.7	21
27	Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance. Medical Oncology, 2021, 38, 72.	2.5	6
28	Caveolin-1 promotes radioresistance in rhabdomyosarcoma through increased oxidative stress protection and DNA repair. Cancer Letters, 2021, 505, 1-12.	7.2	21
29	How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO). Cancers, 2021, 13, 2702.	3.7	4
30	Survival and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy for head and neck cancer: A systematic review and meta-analysis endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Critical Reviews in Oncology/Hematology, 2021, 162, 103345.	4.4	9
31	A Systematic Review on Intensity Modulated Radiation Therapy for Mediastinal Hodgkin's Lymphoma. Critical Reviews in Oncology/Hematology, 2021, 167, 103437.	4.4	9
32	Universal testing for COVID-19 in patients undergoing cancer treatment during the second outbreak in Brescia. Tumori, 2021, , 030089162110349.	1.1	2
33	A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 744956.	2.8	22
34	The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC. Clinical Lung Cancer, 2021, 22, e767-e773.	2.6	8
35	â€~Le Roi est mort, vive le Roi': new roles of radiotherapy in the treatment of lymphomas in combination with immunotherapy Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	5
36	Health-related quality of life 24-month after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study. Minerva Urology and Nephrology, 2021, , .	2.5	3

#	Article	IF	CITATIONS
37	The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of) Tj ETQq1 1 0.784314 2021, 38, 527-537.	rgBT /Ove	rlock 10 Tf 5
38	Three weekly versus weekly concurrent cisplatin: safety propensity score analysis on 166 head and neck cancer patients. Radiation Oncology, 2021, 16, 239.	2.7	4
39	Selection of systemic therapy in patients with locally advanced and recurrent/metastatic head and neck cancer: RAND-based expert opinion by an Italian multidisciplinary panel. Tumori, 2020, 106, 177-189.	1.1	1
40	The role of palliative interventional radiotherapy (brachytherapy) in esophageal cancer: An AIRO (Italian Association of Radiotherapy and Clinical Oncology) systematic review focused on dysphagia-free survival. Brachytherapy, 2020, 19, 104-110.	0.5	18
41	The linguistic validation process of the Vanderbilt Head and Neck Symptom Survey - Italian Version (VHNSS-IT). Radiologia Medica, 2020, 125, 228-235.	7.7	5
42	Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative―intent. Lung Cancer, 2020, 141, 1-8.	2.0	17
43	Back to (new) normality—A CODRAL/AIRO-L survey on cancer radiotherapy in Lombardy during Italian COVID-19 phase 2. Medical Oncology, 2020, 37, 108.	2.5	5
44	Two months of radiation oncology in the heart of Italian "red zone―during COVID-19 pandemic: paving a safe path over thin ice. Radiation Oncology, 2020, 15, 191.	2.7	9
45	Head and neck radiotherapy amid the COVID-19 pandemic: practice recommendations of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Medical Oncology, 2020, 37, 85.	2.5	11
46	A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients. Scientific Reports, 2020, 10, 13589.	3.3	27
47	INTERACTS (INTErventional Radiotherapy ACtive Teaching School) consensus conference on sarcoma interventional radiotherapy (brachytherapy) endorsed by AIRO (Italian Association of Radiotherapy) Tj ETQq1 1 0.	7 84 9314 rg	,) (Overloc
48	In reply to Simcock et al Clinical and Translational Radiation Oncology, 2020, 23, 65.	1.7	1
49	COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Radiotherapy and Oncology, 2020, 149, 89-93.	0.6	43
50	Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab. Clinical Lung Cancer, 2020, 21, e547-e550.	2.6	13
51	Cetuximab and Radiation Therapy Versus Cisplatin and Radiation Therapy for Locally Advanced Head and Neck Cancer: Long-Term Survival and Toxicity Outcomes of a Randomized Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2020, 107, 469-477.	0.8	17
52	Can brachytherapy be properly considered in the clinical practice? Trilogy project: The vision of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) Interventional Radiotherapy study group. Journal of Contemporary Brachytherapy, 2020, 12, 84-90.	0.9	28
53	Letter from Italy: First practical indications for radiation therapy departments during COVID-19 outbreak. International Journal of Radiation Oncology Biology Physics, 2020, 107, 597-599.	0.8	127
54	A pilot study on the Vanderbilt head and neck symptom survey Italian version (VHNSS-IT) to test its feasibility and utility in routine clinical practice. Radiologia Medica, 2020, 125, 423-431.	7.7	4

#	Article	IF	Citations
55	Letter to the Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during COVID-19 pandemic. Radiotherapy and Oncology, 2020, 147, 229-230.	0.6	9
56	Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the) Tj ETQq0 0 C	rgBT/Ove	erlock 10 Tf 50
	2020, 72, 595-604.		
57	The waiting time for prostate cancer treatment in Italy: analysis from the Pros-IT CNR study. Minerva Urology and Nephrology, 2020, , .	2.5	1
58	Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study. Tumori, 2019, 105, 516-523.	1.1	8
59	Recommended ESTRO Core Curriculum for Radiation Oncology/Radiotherapy 4th edition. Radiotherapy and Oncology, 2019, 141, 1-4.	0.6	41
60	Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR). PLoS ONE, 2019, 14, e0224151.	2.5	8
61	Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature. Cancers, 2019, 11, 1284.	3.7	90
62	Cetuximab and Radiation Therapy in Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 678-679.	0.8	2
63	Applying radiation protection and safety in radiotherapy. Radiologia Medica, 2019, 124, 777-782.	7.7	11
64	Current state of interventional radiotherapy (brachytherapy) education in Italy: results of the INTERACTS survey. Journal of Contemporary Brachytherapy, 2019, 11, 48-53.	0.9	26
65	Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial. Journal of Neuro-Oncology, 2019, 143, 447-455.	2.9	6
66	Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events. PLoS ONE, 2019, 14, e0213934.	2.5	7
67	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World Journal of Urology, 2019, 37, 2631-2637.	2.2	69
68	Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO). Critical Reviews in Oncology/Hematology, 2019, 138, 24-28.	4.4	32
69	Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group. Radiologia Medica, 2019, 124, 662-670.	7.7	33
70	Modern radiotherapy in cancer treatment during pregnancy. Critical Reviews in Oncology/Hematology, 2019, 136, 13-19.	4.4	33
71	HAPPY – Humanity Assurance Protocol in interventional radiotheraPY (brachytherapy) – an AIRO Interventional Radiotherapy Study Group project. Journal of Contemporary Brachytherapy, 2019, 11, 510-515.	0.9	7
72	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq0 C Reviews in Oncology/Hematology, 2019, 134, 104-119.	0 rgBT /O 4.4	verlock 10 Tf : 10

#	Article	IF	CITATIONS
73	Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy. Radiologia Medica, 2019, 124, 315-322.	7.7	11
74	Non-palliative radiotherapy in ab initio oligometastatic prostate cancer: an Italian national survey. Radiologia Medica, 2019, 124, 211-217.	7.7	5
75	Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO). Journal of Neuro-Oncology, 2019, 142, 59-67.	2.9	37
76	Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian) Tj ETQq0 0 0 Reviews in Oncology/Hematology, 2019, 134, 87-103.	rgBT /Ove 4.4	erlock 10 Tf 5 7
77	Postoperative radiotherapy for prostate cancer: the sooner the better and potential to reduce toxicity even further. Radiologia Medica, 2018, 123, 63-70.	7.7	13
78	Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO). Radiologia Medica, 2018, 123, 48-62.	7.7	20
79	Reply to  Comment on  Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study''. British Journal of Cancer, 2018, 118, e2-e2.	6.4	0
80	Light and shadows of a new technique: isÂphoton total-skin irradiation using helical IMRT feasible, less complex and as toxic as the electrons one?. Radiation Oncology, 2018, 13, 158.	2.7	11
81	Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study. Medical Oncology, 2018, 35, 121.	2.5	28
82	GUROPA survey: genito-urinary radiation oncology prescription attitudes. Radiologia Medica, 2018, 123, 879-884.	7.7	4
83	Equipment, staffing, and provision of radiotherapy in Lombardy, Italy: Results of three surveys performed between 2012 and 2016. Tumori, 2018, 104, 352-360.	1.1	8
84	Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. Health and Quality of Life Outcomes, 2018, 16, 122.	2.4	24
85	Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2018, 70, 370-379.	3.9	10
86	Exploring the Role of Enzalutamide in Combination with Radiation Therapy: An <i>In Vitro</i> Study. Anticancer Research, 2018, 38, 3487-3492.	1.1	8
87	Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines. Tumori, 2018, 104, 394-400.	1.1	3
88	Oligometastatic prostate cancer patients stratification: A molecular signature identified by liquid biopsy Journal of Clinical Oncology, 2018, 36, TPS400-TPS400.	1.6	3
89	Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience. In Vivo, 2018, 32, 159-164.	1.3	14
90	Pros-IT CNR: an Italian prostate cancer monitoring project. Aging Clinical and Experimental Research, 2017, 29, 165-172.	2.9	26

#	Article	IF	CITATIONS
91	The growing role of biology in the treatment of glioblastoma: no more one kind of disease. Journal of Neuro-Oncology, 2017, 133, 211-212.	2.9	O
92	Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. British Journal of Cancer, 2017, 116, 1520-1525.	6.4	121
93	From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?. Expert Review of Anticancer Therapy, 2017, 17, 157-165.	2.4	0
94	Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease. Critical Reviews in Oncology/Hematology, 2017, 117, 48-56.	4.4	12
95	Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 462-472.	0.8	35
96	Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR. European Urology Focus, 2017, 3, 321-324.	3.1	15
97	A Neuro-Oncologic Challenge: The Case of a Large, Aggressive, Malignant Meningioma of the Skull Base with Paranasal Sinus Involvement. Tumori, 2016, 102, S5-S8.	1.1	2
98	Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: Could a margin reduction be proposed?. Journal of Neuro-Oncology, 2016, 128, 303-312.	2.9	21
99	In reply to Borras et al. The strengthening of Radiation Oncologist role inside multidisciplinary arena within 2025. Radiotherapy and Oncology, 2016, 119, 369.	0.6	O
100	Extreme hypofractionation for early prostate cancer: Biology meets technology. Cancer Treatment Reviews, 2016, 50, 48-60.	7.7	40
101	Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions. British Journal of Radiology, 2016, 89, 20150981.	2.2	27
102	Resected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy. Radiologia Medica, 2016, 121, 696-703.	7.7	4
103	Radiobiology as a Basic and Clinical Medical Science: What the Physicists have Forgotten. Tumori, 2016, 102, e8-e8.	1.1	2
104	The "Radioresistance―of Glioblastoma in the Clinical Setting, and the Present Therapeutic Options. Current Clinical Pathology, 2016, , 15-27.	0.0	0
105	Whole brain radiotherapy with adjuvant or concomitant boost in brain metastasis: dosimetric comparison between helical and volumetric IMRT technique. Radiation Oncology, 2016, 11, 59.	2.7	15
106	Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial. Journal of Clinical Oncology, 2016, 34, 427-435.	1.6	203
107	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. Critical Reviews in Oncology/Hematology, 2016, 102, 47-54.	4.4	51
108	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement. Critical Reviews in Oncology/Hematology, 2016, 97, 131-142.	4.4	82

#	Article	IF	CITATIONS
109	Clinical outcomes and toxicity after exclusive versus postoperative radiotherapy in supraglottic cancer: new solutions for old problems? The case of stage III and IV disease. Radiologia Medica, 2016, 121, 70-79.	7.7	8
110	BONADIUV trial: A single blind, randomized placebo controlled phase II study using oral ibandronate for osteopenic women receiving adjuvant aromatase inhibitors: Final safety analysis Journal of Clinical Oncology, 2016, 34, e12043-e12043.	1.6	2
111	Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature. Anticancer Research, 2016, 36, 2975-81.	1.1	8
112	Reirradiation in Head and Neck Recurrent or Second Primary Tumor: Efficacy, Safety, and Prognostic Factors. Tumori, 2015, 101, 585-592.	1.1	22
113	Optimizing Radiation Treatment Decisions for Patients Who Receive Neoadjuvant Chemotherapy. Journal of the National Cancer Institute Monographs, 2015, 2015, 9-10.	2.1	1
114	Could Concomitant Radio-Chemotherapy Improve the Outcomes of Early-Stage Node Negative Anal Canal Cancer Patients? A Retrospective Analysis of 122 Patients. Cancer Investigation, 2015, 33, 114-120.	1.3	10
115	Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1077-1083.	0.8	28
116	The treatment of patients with $1\hat{a}\in$ "3 brain metastases: is there a place for whole brain radiotherapy alone, yet? A retrospective analysis. Radiologia Medica, 2015, 120, 1146-1152.	7.7	8
117	Radiotherapy for adult medulloblastoma: Long term result from a single institution. A review of prognostic factors and why we do need a multi-institutional cooperative program. Reports of Practical Oncology and Radiotherapy, 2015, 20, 284-291.	0.6	16
118	Post-surgical therapeutic approaches to glioblastoma patients submitted to biopsy (BA) or "partial― resection (PR): the possibilities to treat also them without renunciations. Study from the Brescia Neuro-Oncology Group. Radiologia Medica, 2015, 120, 975-981.	7.7	1
119	Clinical outcomes and toxicity after exclusive versus postoperative radiotherapy in supraglottic cancer: new solutions for old problems? The case of stage I and II disease. Radiologia Medica, 2015, 120, 1071-1077.	7.7	6
120	Circulating Tumor Cells in Patients with Recurrent or Metastatic Head and Neck Carcinoma: Prognostic and Predictive Significance. PLoS ONE, 2014, 9, e103918.	2.5	69
121	External Beam Radiotherapy $\hat{A}\pm$ Chemotherapy in the Treatment of Anal Canal Cancer: A Single-Institute Long-Term Experience on 100 Patients. Cancer Investigation, 2014, 32, 248-255.	1.3	6
122	Radiotherapy equipment and departments in the European countries: Final results from the ESTRO-HERO survey. Radiotherapy and Oncology, 2014, 112, 155-164.	0.6	140
123	Guidelines for equipment and staffing of radiotherapy facilities in the European countries: Final results of the ESTRO-HERO survey. Radiotherapy and Oncology, 2014, 112, 165-177.	0.6	61
124	Reliability of prostate-specific antigen-marker in determining biochemical failure during the first 2 years after external beam radiation therapy and hormone therapy in patients with non-operated prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 30.e1-30.e7.	1.6	6
125	Salvage therapy of small volume prostate cancer nodal failures: A review of the literature. Critical Reviews in Oncology/Hematology, 2014, 90, 24-35.	4.4	25
126	Radiotherapy in low-grade glioma adult patients: a retrospective survival and neurocognitive toxicity analysis. Radiologia Medica, 2014, 119, 432-439.	7.7	11

#	Article	IF	CITATIONS
127	Role of external beam radiotherapy in the treatment of relapsing meningioma. Medical Oncology, 2014, 31, 866.	2.5	14
128	The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indications. Reports of Practical Oncology and Radiotherapy, 2014, 19, 77-91.	0.6	20
129	Changes in Patterns of Practice for Prostate Cancer Radiotherapy in Italy 1995–2003. A Survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society. Tumori, 2014, 100, 31-37.	1.1	7
130	Changes in patterns of practice for prostate cancer radiotherapy in Italy 1995-2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society. Tumori, 2014, 100, 31-7.	1.1	6
131	Three-dimensional conformal radiotherapy, static intensity-modulated and helical intensity-modulated radiotherapy in glioblastoma. Dosimetric comparison in patients with overlap between target volumes and organs at risk. Tumori, 2014, 100, 272-7.	1.1	8
132	Retreatment of recurrent adult medulloblastoma with radiotherapy: a case report and review of the literature. Journal of Medical Case Reports, 2013, 7, 64.	0.8	9
133	Predictive factors for oropharyngeal mycosis during radiochemotherapy for head and neck carcinoma and consequences on treatment duration. Results of mycosis in radiotherapy (MIR): A prospective longitudinal study. Radiotherapy and Oncology, 2013, 109, 303-310.	0.6	5
134	Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: A review. Critical Reviews in Oncology/Hematology, 2013, 88, 550-563.	4.4	52
135	In haematopoietic SCT for acute leukemia TBI impacts on relapse but not survival: results of a multicentre observational study. Bone Marrow Transplantation, 2013, 48, 908-914.	2.4	15
136	Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. Neuro-Oncology, 2013, 15, 618-625.	1.2	64
137	Role of new radiation techniques in the treatment of pleural mesothelioma. Thoracic Cancer, 2013, 4, 219-228.	1.9	O
138	Exploiting Machine Learning for Predicting Nodal Status in Prostate Cancer Patients. IFIP Advances in Information and Communication Technology, 2013, , 61-70.	0.7	2
139	Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). Neuro-Oncology, 2012, 14, 798-807.	1.2	26
140	The updated ESTRO core curricula 2011 for clinicians, medical physicists and RTTs in radiotherapy/radiation oncology. Radiotherapy and Oncology, 2012, 103, 103-108.	0.6	81
141	Circulating Tumour Cells in locally advanced head and neck cancer: Preliminary report about their possible role in predicting response to non-surgical treatment and survival. European Journal of Cancer, 2012, 48, 3019-3026.	2.8	92
142	In reply to L. Ceresoli et al. "Adjuvant radiotherapy for malignant pleural mesothelioma: Challenges and pitfalls― Radiotherapy and Oncology, 2012, 105, 272.	0.6	0
143	Second Malignancies following Breast Cancer Treatment: A Case-Control Study Based on the Peridose Methodology. ALLEGRO Project (Task 5.4). Tumori, 2012, 98, 715-721.	1.1	2
144	Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. Strahlentherapie Und Onkologie, 2012, 188, 216-225.	2.0	25

#	Article	IF	CITATIONS
145	A benchmark study on 883 nasopharyngeal cancer patients treated in two Italian Centres from 1977 to 2000. Part I: evolving technical choices and survival. Radiologia Medica, 2012, 117, 690-714.	7.7	3
146	A benchmark study on 883 nasopharyngeal cancer patients treated in two Italian Centres from 1977 to 2000. Part II: evolving technical choices and toxicity patterns. Radiologia Medica, 2012, 117, 715-724.	7.7	1
147	The impact of tumour histology and recursive partitioning analysis classification on the prognosis of patients treated with whole-brain hypofractionated radiotherapy for brain metastases: analysis of 382 patients. Radiologia Medica, 2012, 117, 133-147.	7.7	5
148	Limited-stage small-cell lung cancer treated with early chemo-radiotherapy: the impact of effective chemotherapy. Tumori, 2012, 98, 53-9.	1,1	1
149	Second malignancies following breast cancer treatment: a case-control study based on the Peridose methodology. Allegro project (task 5.4). Tumori, 2012, 98, 715-21.	1.1	O
150	Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiotherapy and Oncology, 2011, 99, 356-361.	0.6	83
151	Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series. Radiotherapy and Oncology, 2011, 101, 311-315.	0.6	49
152	Expert Opinions of the First Italian Consensus Conference on the Management of Malignant Pleural Mesothelioma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 99-109.	1.3	17
153	Patterns of Care and Survival in a Retrospective Analysis of 1059 Patients With Glioblastoma Multiforme Treated Between 2002 and 2007. Neurosurgery, 2010, 67, 446-458.	1.1	73
154	Transdermal Buprenorphine for Oropharyngeal Mucositis-Associated Pain in Patients Treated with Radiotherapy for Head and Neck Cancer. Journal of Palliative Medicine, 2010, 13, 357-358.	1,1	2
155	Effects of fluconazole in the prophylaxis of oropharyngeal candidiasis in patients undergoing radiotherapy for head and neck tumour: results from a double-blind placebo-controlled trial. European Journal of Cancer Care, 2008, 17, 270-277.	1.5	17
156	Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study. Annals of Oncology, 2008, 19, 951-957.	1.2	2
157	Open-source, low-cost, high-reliability solutions for digital imaging systems: Example of a "dicom router― Radiologia Medica, 2007, 112, 1252-1259.	7.7	4
158	Primary Thyroid Lymphoma: A Retrospective IELSG and IIL Analysis of Clinical Characteristics, Prognostic Factors, Treatment Outcome and Somatic Hypermutation for Localized Diffuse Large B-Cell Lymphoma (DLBCL) Blood, 2007, 110, 3432-3432.	1.4	0
159	Radical Radiotherapy For Bladder Cancer: Retrospective Analysis of a Series of 459 Patients Treated in an Italian Institution. Clinical Oncology, 2006, 18, 52-59.	1.4	22
160	Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers. International Journal of Radiation Oncology Biology Physics, 2006, 65, 788-799.	0.8	23
161	Impact of radiotherapy technique on the outcome of early breast cancer treated with conservative surgery: A multicenter observational study on 1,176 patients. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1361-1367.	0.8	8
162	Postoperative radiotherapy after radical prostatectomy for prostate carcinoma: the experience of the Brescia Radium Institute. Radiologia Medica, 2006, 111, 741-747.	7.7	6

#	Article	IF	CITATIONS
163	Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2NO disease. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1387-1394.	0.8	88
164	Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1NO disease. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1378-1386.	0.8	114
165	Localized Extranodal Lymphoma of the Head and Neck: Retrospective Analysis of a Series of 107 Patients from a Single Institution. Tumori, 2005, 91, 456-462.	1.1	18
166	Which Role for Radiation Therapy in Ethmoid Cancer? A Retrospective Analysis of 84 Cases from a Single Institution. Tumori, 2004, 90, 573-578.	1.1	2
167	In regard to Cozzarini et al.: Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: A single-institute experience of 415 patients (Int J Radiat Oncol Biol) Tj ETQq1 1	@ 7 884314	∮ œ BT/Ov <mark>er</mark> i
168	Stage I seminoma of the testis: a biâ€institutional retrospective analysis of patients treated with radiation therapy only. BJU International, 2003, 92, 47-52.	2.5	50
169	Practice patterns for prostate cancer in nine central and northern Italy radiation oncology centers: a survey including 1759 patients treated during two decades (1980–1998). International Journal of Radiation Oncology Biology Physics, 2002, 52, 1310-1319.	0.8	17
170	Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiotherapy and Oncology, 2001, 59, 247-255.	0.6	92
171	The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hospital. International Journal of Radiation Oncology Biology Physics, 2001, 49, 1327-1337.	0.8	25
172	Real-Time Quantitative Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) for the Measurement of Prostate-Specific Antigen mRNA in the Peripheral Blood of Patients with Prostate Carcinoma Using the TaqManTM Detection System. Clinical Chemistry and Laboratory Medicine, 2001, 39, 385-91.	2.3	28
173	Comparison of the conventional  box technique' with two different  conformal' beam arrangements for prostate cancer treatment. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 1999, 3, 215-220.	1.4	5
174	Radical radiotherapy of localised prostate cancer: the relationship between radiation dose and survival. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 1998, 2, 351-358.	1.4	9
175	Second solid tumors and leukemia after treatment for Hodgkin's disease: An analysis of 1121 patients from a single institution. International Journal of Radiation Oncology Biology Physics, 1994, 29, 25-31.	0.8	86
176	Chordoma-Natural History, Treatment and Prognosis the Florence Radiotherapy Department Experience (1956-1990) and a Critical Review of the Literature. Acta Oncológica, 1992, 31, 847-851.	1.8	59
177	Chemotherapy versus radiotherapy in early-stage Hodgkin's disease: Evidence of a more difficult rescue for patients relapsed after chemotherapy. European Journal of Cancer, 1992, 28, 1853-1855.	2.8	13
178	Merkel cell carcinoma and iodine-131 metaiodobenzylguanidine scan. European Journal of Nuclear Medicine and Molecular Imaging, 1992, 19, 913-916.	2.1	12
179	Merkel cell carcinoma: Report of two cases and clinical considerations. Journal of Surgical Oncology, 1992, 49, 131-134.	1.7	5
180	Association Between Testicular Cancer and Spina Bifida Occulta. Acta Oncológica, 1991, 30, 579-581.	1.8	6

#	Article	IF	CITATIONS
181	Long-term nervous system damage from radiation of the spinal cord: An electrophysiological study. Journal of Neurology, 1991, 238, 9-15.	3.6	17
182	Neurological damage in patients irradiated twice on the spinal cord: a morphologic and electrophysiological study. Radiotherapy and Oncology, 1990, 17, 209-218.	0.6	15
183	Brain Damage After Treatment for Acute Lymphoblastic Leukemia a Report on 34 Patients with Special Regard to Mri Findings. Acta Oncológica, 1989, 28, 253-256.	1.8	17
184	Carboplatin (JM8), etoposide (VP16) and thoracic Irradiation for small cell lung cancer (S.C.L.C.): An evaluation of lung toxicity. Radiotherapy and Oncology, 1988, 12, 31-37.	0.6	10
185	Stage I and II Hodgkin's Disease Presenting in Infradiaphragmatic Nodes. Tumori, 1982, 68, 519-525.	1.1	24